BR112012025475B8 - sais do ácido 1-ciclopropil-8-metil-7-[5-metil-6-(metilamino)-3-piridinil]-4-oxo-1,4-di-hidro-3-quinolinacarboxílico, seu uso e composição farmacêutica que os compreende - Google Patents

sais do ácido 1-ciclopropil-8-metil-7-[5-metil-6-(metilamino)-3-piridinil]-4-oxo-1,4-di-hidro-3-quinolinacarboxílico, seu uso e composição farmacêutica que os compreende

Info

Publication number
BR112012025475B8
BR112012025475B8 BR112012025475A BR112012025475A BR112012025475B8 BR 112012025475 B8 BR112012025475 B8 BR 112012025475B8 BR 112012025475 A BR112012025475 A BR 112012025475A BR 112012025475 A BR112012025475 A BR 112012025475A BR 112012025475 B8 BR112012025475 B8 BR 112012025475B8
Authority
BR
Brazil
Prior art keywords
methyl
pyridinyl
cyclopropyl
oxo
salts
Prior art date
Application number
BR112012025475A
Other languages
English (en)
Other versions
BR112012025475A2 (pt
BR112012025475A8 (pt
BR112012025475B1 (pt
Inventor
Palomer Albert
Anglada Luis
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of BR112012025475A2 publication Critical patent/BR112012025475A2/pt
Publication of BR112012025475A8 publication Critical patent/BR112012025475A8/pt
Publication of BR112012025475B1 publication Critical patent/BR112012025475B1/pt
Publication of BR112012025475B8 publication Critical patent/BR112012025475B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

sais do ácido 1-ciclopropil-8-metil-7-[5-metil-6-(metilamo)-3-piridinil]-4-oxo-1,4-di-hidro-3-quinolinacarboxílico. a presente invenção refere-se a um sal que é fornecido do ácido 1-ciclopropil-8-metil-7-[5-metil-6-(metilamino)-3-piridinil]-4-oxo-1,4-di-hidro-3-quinolinacarboxílico selecionado do grupo consistindo dos sais citrato, hemifuramato, meleato, l-tartrato, mesilato, cloridrato, potássio e sódio.
BR112012025475A 2010-04-06 2010-04-06 sais do ácido 1-ciclopropil-8-metil-7-[5-metil-6-(metilamino)-3-piridinil]-4-oxo-1,4-di-hidro-3-quinolinacarboxílico, seu uso e composição farmacêutica que os compreende BR112012025475B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/054506 WO2011124249A1 (en) 2010-04-06 2010-04-06 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts

Publications (4)

Publication Number Publication Date
BR112012025475A2 BR112012025475A2 (pt) 2016-06-21
BR112012025475A8 BR112012025475A8 (pt) 2017-10-17
BR112012025475B1 BR112012025475B1 (pt) 2021-04-27
BR112012025475B8 true BR112012025475B8 (pt) 2021-05-25

Family

ID=42953867

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012025475A BR112012025475B8 (pt) 2010-04-06 2010-04-06 sais do ácido 1-ciclopropil-8-metil-7-[5-metil-6-(metilamino)-3-piridinil]-4-oxo-1,4-di-hidro-3-quinolinacarboxílico, seu uso e composição farmacêutica que os compreende

Country Status (19)

Country Link
US (1) US8507684B2 (pt)
EP (1) EP2556063B1 (pt)
JP (1) JP5836360B2 (pt)
KR (1) KR101667089B1 (pt)
CN (1) CN102884058B (pt)
AU (1) AU2010350521B2 (pt)
BR (1) BR112012025475B8 (pt)
CA (1) CA2794252C (pt)
CY (1) CY1116735T1 (pt)
DK (1) DK2556063T3 (pt)
ES (1) ES2548989T3 (pt)
HK (1) HK1180321A1 (pt)
HU (1) HUE026460T2 (pt)
MX (1) MX2012011394A (pt)
PL (1) PL2556063T3 (pt)
PT (1) PT2556063E (pt)
RU (1) RU2515557C9 (pt)
SI (1) SI2556063T1 (pt)
WO (1) WO2011124249A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015166387A (ja) * 2015-06-08 2015-09-24 フエルレル インターナショナル，ソシエダッド アノニマ １‐シクロプロピル‐８‐メチル‐７‐［５‐メチル‐６‐（メチルアミノ）‐３‐ピリジニル］‐４‐オキソ‐１，４‐ジヒドロ‐３‐キノリンカルボン酸塩
CN107121506B (zh) * 2017-04-13 2019-06-07 杭州华东医药集团新药研究院有限公司 奥泽沙星杂质及其用途
WO2020065668A1 (en) * 2018-09-26 2020-04-02 Maithri Drugs Pvt Ltd Crystalline form of ozenoxacin and processes for preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1519529A3 (ru) * 1985-10-29 1989-10-30 Дайниппон Фармасьютикал Ко., Лтд (Фирма) Способ получени производного хинолина, его фармацевтически приемлемого сложного эфира или фармацевтически приемлемой соли производного хинолина или сложного эфира
BRPI9909456B8 (pt) * 1998-04-06 2021-07-06 Toyama Chemical Co Ltd Ácido quinolonecarboxílico ou sais dos mesmos
JP4293755B2 (ja) * 2001-03-26 2009-07-08 富山化学工業株式会社 ピリドンカルボン酸系化合物を含有する皮膚外用剤
JP4384402B2 (ja) 2001-11-30 2009-12-16 富山化学工業株式会社 デスフルオロピリドンカルボン酸系化合物を含有する水溶液剤およびその粉末化物並びにそれら製造方法
PL1731138T3 (pl) 2004-03-31 2016-10-31 Drobnoziarnista dyspersja słabo rozpuszczalnego leku i sposób jej wytwarzania
JP4393552B2 (ja) 2005-08-01 2010-01-06 マルホ株式会社 ピリドンカルボン酸誘導体を含有するローション剤
JP5112669B2 (ja) 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤

Also Published As

Publication number Publication date
WO2011124249A1 (en) 2011-10-13
DK2556063T3 (en) 2015-09-28
PL2556063T3 (pl) 2015-12-31
CN102884058B (zh) 2014-08-20
US8507684B2 (en) 2013-08-13
BR112012025475A2 (pt) 2016-06-21
HK1180321A1 (en) 2013-11-29
CN102884058A (zh) 2013-01-16
SI2556063T1 (sl) 2015-10-30
EP2556063A1 (en) 2013-02-13
EP2556063B1 (en) 2015-07-01
KR20130039316A (ko) 2013-04-19
MX2012011394A (es) 2012-11-29
CA2794252A1 (en) 2011-10-13
PT2556063E (pt) 2015-10-22
CA2794252C (en) 2015-06-23
JP2013523786A (ja) 2013-06-17
HUE026460T2 (en) 2016-05-30
US20130040989A1 (en) 2013-02-14
RU2515557C1 (ru) 2014-05-10
ES2548989T3 (es) 2015-10-22
JP5836360B2 (ja) 2015-12-24
RU2515557C9 (ru) 2014-06-27
AU2010350521B2 (en) 2015-04-16
AU2010350521A1 (en) 2012-11-01
KR101667089B1 (ko) 2016-10-17
BR112012025475A8 (pt) 2017-10-17
BR112012025475B1 (pt) 2021-04-27
CY1116735T1 (el) 2017-03-15

Similar Documents

Publication Publication Date Title
BR112015003376A8 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
BR112015028538A2 (pt) derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b
BR112016012465A8 (pt) sal, método de preparação do sal e composição farmacêutica
BR112013027670A2 (pt) "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory"
BR112014014740A2 (pt) composto, composição farmacêutica, método para melhorar ou tratar infecção viral, para inibir a replicação de vírus ou tratar infecção viral e usos quantidade efetiva de composto ou de sal farmaceuticamente aceitável deste ou de composição farmacêutica
BR112014014769A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou sal.
BR112014013108A2 (pt) compostos tricíclicos fundidos como inibidores da quinase raf
BR112012017402A2 (pt) inibidores de vírus de flaviviridae
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BR112012022873A2 (pt) formulações orais e sais lipofílicos de metilnaltrexona
BR112013030045A2 (pt) composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente
BR112015007061A8 (pt) composto, composição farmacêutica e uso do composto
CO6930364A2 (es) Composiciones farmaceúticas que comprenden 40-o-(2-hidroxi) etil - rapamicina
BR112015021524A2 (pt) derivados de sulfonil quinolina e usos dos mesmos
BR112016009488A8 (pt) piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica.
BR112013022556A8 (pt) composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol
AR093335A1 (es) Sales amina de laquinimod
BR112014002845A2 (pt) “composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto”
BR112014021828B8 (pt) Sal de alcaloide bisquaternário
BR112014008668A2 (pt) moduladores de receptor de andrógeno seletivo
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112014028121A2 (pt) n-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
BR112014018738A8 (pt) Métodos e intermediários para preparo de agentes farmacêuticos
BR112016013776A2 (pt) Composto derivado do ácido 3-(5-cloro-2-oxibenzo[d]oxazol-3(2h)-il)propanoico ou um sal deste, uso terapêutico do mesmo e composição farmacêutica compreendendo o referido composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2769 DE 30-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.